Novo Nordisk’s CEO Mike Doustdar warned investors that the company will face growing challenges in its international business during 2026. Competition is intensifying in key European and Asia-Pacific markets following the loss of market exclusivity for its blockbuster GLP-1 therapy in at least five major countries. Management expects pricing pressure to widen by 3–5 percentage points and volume growth to slow from the current double-digit rate to mid-single digits over the next two quarters. Despite these headwinds, Novo Nordisk plans to offset revenue erosion through geographic expansion in Latin America and the Middle East, aiming to add €500 million in annual sales by year-end 2026.

The U.S. Food and Drug Administration reported that its initial assessment found no clear connection between GLP-1 receptor agonists and suicidal thoughts or behavior. The agency reviewed adverse-event reports and clinical-trial data covering more than 20,000 patients treated with GLP-1 therapies—including Novo Nordisk’s weight-management products—and found that reported psychiatric events occurred at similarly low rates in both treatment and control groups. While the FDA continues a comprehensive meta-analysis of all GLP-1 trials and is mining post-marketing data through its Sentinel System database, it emphasized that health-care providers and patients should follow current prescribing guidelines and report any new or worsening mood changes. Final safety conclusions are expected in mid-2026.